MTx is an innovator in the field of antibody discovery and immune repertoire analysis. Our antibody discovery platform DROPZYLLA® uses robust, simple, and fast microfluidic single-cell technologies to enable antibody repertoire mining and mAb discovery at unprecedented efficiency and speed.
Products, services, technology
The company’s current pipeline features programs in transplant virology and immuno-oncology. mAb “AntiBKV” is currently in clinical development for the treatment of BK polyomavirus infection in kidney transplant recipients.
Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery from human and animal species across all indications for proprietary and partnered projects.